Media.Player

Detection of vWF Cleaving Protease

Technology Benefits

Rapid and reproducible measurement of ADAMT13 levels in asolid phase assay using a colorimetric end point.

Technology Application

Companies interested in diagnostic testing, molecular analysis,and clotting disease.Test mass production.

Detailed Technology Description

This diagnostic method is used to measurecongenital or acquired deficiency of ADAMTS13, a cationdependent protease that cleaves vonWillebrand factor (vWf), isimplicated as the cause of thrombotic thrombocytopenic purpura(TTP). Measurement of ADAMTS13 levels are useful in thediagnosis and management of TTP. Current methods of detectingADAMTS13 are based on the ability of the protease to cleaveintact vWf and are cumbersome and not always reproducible. Thispatent application describes detection and measurement ofADAMTS13 on the basis of its ability to cleave a synthetic peptidecontaining the cleavage site at which the protease acts.Exclusively licensed worldwide. Partnership opportunities will beconsidered. US patents and foreign country applications currentlyin prosecution.

*Abstract

This diagnostic method is used to measurecongenital or acquired deficiency of ADAMTS13, a cationdependent protease that cleaves vonWillebrand factor (vWf), isimplicated as the cause of thrombotic thrombocytopenic purpura (TTP).

*Principal Investigator

Name: Robert R. Montgomery

Department:

Name: Sandra Haberichter

Department:

Name: Thomas Raife

Department:

Country/Region

USA